Pharmaceutical - Inlyta

Filter

Current filters:

Inlyta

Popular Filters

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

04-03-2014

UK drug watchdog the National Institute for Health and Care Excellence (NICE) this morning published…

InlytaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Regulator backs Inlyta, Lucentis and Xtandi for NHS Scotland, but not Bosulif

12-11-2013

The Scottish Medicines Consortium (SMC) revealed this morning (November 12) that it has accepted US drug…

Astellas PharmaBosulifEuropeInlytaLucentisNovartisOncologyOphthalmicsPfizerPharmaceuticalRegulationXtandi

NICE denies NHS use of Pfizer's Inlyta for patients with terminal kidney cancer

28-03-2013

In a second disappointment from the agency this week, US drugs behemoth Pfizer (NYSE: PFE) Ltd expressed…

EuropeInlytaOncologyPfizerPharmaceuticalPricingRegulation

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

Pfizer's Inlyta misses primary endpoint in Ph III kidney cancer trial

18-10-2012

US drugs behemoth Pfizer (NYSE: PFE) revealed yesterday that a Phase III study of Inlyta axitinib) did…

InlytaOncologyPfizerPharmaceuticalResearch

European approval for Pfizer's kidney cancer drug Inlyta

05-09-2012

The European Commission yesterday granted marketing authorization for Pfizer's (NYSE: PFE) Inlyta (axitinib)…

EuropeInlytaOncologyPfizerPharmaceuticalRegulation

Back to top